Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telsar Pharma Inc.

Latest From Telsar Pharma Inc.

Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets

Astellas’ multi-track R&D approach leaves door open for a Western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.

BioPharmaceutical Japan

Astellas Shuts U.S./EU Phase III Trial But Resumes Asia Development For Differentiated Markets

Astellas’ multi-track R&D approach leaves door open for a western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.

BioPharmaceutical Japan

Start-Up Quarterly Statistics, Q2 2012

In the second quarter of 2012, start-up companies raised a total of $556 million across all industries. Most of that financing – $439.8 million – went to the biopharma sector. Cancer was the most prevalent therapeutic area for alliances. There were just four start-up acquisitions – two each in the biopharma and medical device industries.

BioPharmaceutical Medical Device

Biopharma Quarterly Deal Statistics, Q2 2012

Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Telsar Pharma Inc.
  • Senior Management
  • Donna L Tempel, PhD, Pres. & CEO
    Robert E Desjardins, MD, CSO
  • Contact Info
  • Telsar Pharma Inc.
    ,
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register